Quality Assurance in Europe: Analysing Tablet Compaction to Enhance...
Pharma Tech Outlook

Quality Assurance in Europe: Analysing Tablet Compaction to Enhance Manufacturing Performance

Pharma Tech Outlook | Tuesday, October 06, 2026

Consistent product quality, reliable production processes and careful material performance assessment before medicines are administered to patients are necessary for pharmaceutical manufacturing. Each tablet should exhibit a high level of strength, uniformity and stability and be appropriate for mass production. That degree of uniformity can only be attained by knowledge of the behaviour of powder blends during compression.

The tablet compaction analyser system, the new addition in Europe, has been an essential tool for scientists to assess compaction properties, formulate and enhance the efficiency of tablet manufacturing processes. An improved understanding of the process will enable manufacturers to make informed formulation decisions and help ensure product quality throughout development and commercial manufacturing.

Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.

Emerging Developments across Pharmaceutical Compression Analysis

Understanding how a material behaves before production has become an important part of pharmaceutical development. European researchers are paying closer attention to how formulation properties influence both manufacturing efficiency and the quality of the finished product. During the early stages of development, they carefully evaluate factors such as powder flow, compressibility and mechanical strength to reduce potential issues before production is scaled up. A better understanding of these characteristics supports more confident formulation decisions and helps create a smoother product development process.

The process of automation is further changing the way lab operations work by enabling consistent measurement and minimising manual variation during material analysis. Modern analytical equipment will enable repeatable testing and can also be used to compare the performance of formulations under varying compression conditions. Scientific understanding is reinforced with greater analytical precision and can help to make more reliable manufacturing outcomes.

“The tablet compaction analyser system has been an essential tool for scientists to assess compaction properties, formulate and enhance the efficiency of tablet manufacturing processes.”

The importance of closer interaction between formulation scientists, process engineers, and quality specialists has grown more significant along the pharmaceutical development process. Technical know-how is shared, which enables formulation decisions to be made that take into account both product performance needs and manufacturing requirements. Improved communication provides more efficient development and enables more practical solutions that enhance product reliability in various production environments.

Solving Formulation Challenges through Better Process Understanding

The process of developing reliable tablet formulations is delicate and requires careful evaluation, as different pharmaceutical ingredients behave differently during compression into tablets. The characteristics of the material, like particle size, moisture content and powder density, can affect the tablet strength and process performance. The material characterisation and the controlled laboratory testing, combined with the detailed formulation analysis, enable scientists to choose the right compression conditions and to increase the consistency of the products and manufacturing efficiency.

Careful control of the process is also important to ensure uniformity of tablet quality from batch to batch, since there may be slight differences in formulation behaviour that can affect hardness, friability and dissolution. If the material behaviour isn't fully understood, inconsistent compression conditions can impact manufacturing efficiency. Standardised analytical processes, ongoing evaluation of the processing and detailed compression studies enable manufacturers to obtain reliable product quality and, at the same time, enable efficient production.

Formulation development is a delicate process that must consider the formulation performance and the manufacturing efficiency, as the two must be closely correlated. Optimisation for performance in the laboratory may need to be repeated during commercial manufacture. Process development, manufacturing simulation and collaborative formulation review enable research teams to develop products that can be reliably produced throughout manufacturing.

Advanced analytical capability is also necessary for the management of increasingly complex pharmaceutical formulations, as modern medicines often contain a number of active and inactive ingredients with different physical properties. The knowledge of the response of individual components during compression will assist the researchers in making informed adjustments to the formulation prior to large-scale production. Laboratory evaluation enhances scientific understanding and boosts manufacturing confidence.

Innovation Expanding the Future of Pharmaceutical Analysis

Artificial intelligence is an essential tool in pharmaceutical research, assisting scientists in organising analytical data, identifying formulation patterns, and evaluating compression performance more efficiently. Intelligent systems can process large volumes of laboratory data and highlight meaningful insights that support scientific decision-making. Rather than replacing expert knowledge, AI helps researchers work more efficiently while allowing them to focus on formulation development and product quality.

Additional sensors continue to develop and give more accurate readings during compression testing in the lab. New monitoring systems provide more detailed data about how materials react to different pressures, enabling researchers to test the performance of their formulation confidently. Better accuracy in measurement helps to optimise the formulation and provides better confidence in manufacturing.

Predictive modelling is also gaining more and more importance in formulation development for pharmaceutical systems. Laboratory test data can be used in conjunction with computational analysis to predict the performance of the formulation prior to full production. More predictive ability leads to efficient use of resources, decreased uncertainty in development and increased understanding of the process.

Analytical software is continually getting better and better, which is enabling laboratories to interpret increasingly complex data better. Advanced visualisation tools enable better identification of formulation trends, comparison of material behaviour and evaluation of compression results. Improved analytical insight leads to increased confidence in formulation decision-making and contributes to strong product development strategies.

More in News

A drug discovery platform can process thousands of compounds and still leave a program with weak evidence about what will matter in patients. Throughput is useful only when the biological readout has enough disease relevance to justify the next experiment. For executives, model choice deserves close scrutiny. A system built around a narrowly defined target may move quickly yet miss compounds that improve a disease phenotype through mechanisms that are incomplete or not fully understood. Phenotypic screening can widen the search, but only if the model produces measurable effects at a pace suitable for disciplined screening. The practical comparison is between volume and interpretability. A fast assay that generates ambiguous hits can create more downstream work, while a slower but biologically coherent screen may reduce expensive follow-up. The next concern is how hits move from initial detection into a more credible development path. A useful platform should make that progression visible. Primary screening needs a clear readout, while secondary screening should test whether an observed effect holds under another biologically relevant condition. Structure-activity work then becomes more valuable because compound changes can be judged against an established phenotype rather than computational preference alone. Executives should look for a process that can reject weak candidates early and still preserve promising chemistry for further refinement. The handoff matters when a program moves from screening into preclinical work. Poorly connected stages can leave teams repeating experiments because the basis for advancing a compound was never clear enough. “Gilga-Med’s structure-activity work uses AI to predict and generate new small molecules from experimental data produced by the platform, keeping computation tied to measured biological effects.” Small-molecule discovery also raises a different tradeoff around specificity. Compounds that affect more than one pathway can create side-effect risk, yet diseases involving aging or proteotoxic stress may not reduce neatly to a single molecular target. The better question is whether the platform can distinguish useful multi-pathway activity from uncontrolled pharmacology. Evidence should show that structural features can be adjusted while the desired biological effect is retained. A discovery system that supports iterative chemistry around observed function gives development teams more room to manage that tradeoff. Artificial intelligence adds little when it is detached from proprietary experimental data. Its practical use increases when models are trained on repeated structure-activity relationships tied to measured phenotypes. That connection matters because prediction should shorten the next design cycle, not merely produce more candidate structures. Executives should examine how experimental results feed back into compound generation and whether each round creates information that sharpens the following one. The strongest platforms treat computation as part of a closed discovery loop rather than a substitute for biological testing. Long-term advantage comes from accumulating experimentally grounded relationships that make future predictions more specific to the platform’s own chemistry. Gilga-Med uses high-throughput phenotypic screening in C. elegans disease models to identify small molecules based on observed biological effects rather than a predefined target. Its discovery process starts with primary screening and uses secondary assays to test promising hits. Structure-activity refinement follows. Its structure-activity work uses AI to predict and generate new small molecules from experimental data produced by the platform, keeping computation tied to measured biological effects. The same process produced GM310, which advanced into a mouse model of hemorrhagic stroke after earlier screening work. Gilga-Med is most relevant to buyers that favor phenotype-led discovery when target biology remains uncertain. For programs built around that scientific premise, it merits serious consideration. ...Read more
Industry Overview Drug manufacturing is heading into a stretch defined by supply chain resilience, newer production technologies, tougher quality expectations and rising demand for complex medicines. Companies are putting money into biologics, advanced therapies, continuous production and digital systems, and regulators want to see mature quality management. A modern pharmaceutical facility is no longer just a production site. It’s a connected system built around quality, reliability, flexibility and traceability. Supply Resilience Becomes a Manufacturing Priority Recent disruptions exposed weak points in concentrated manufacturing networks and in reliance on a few suppliers. Drugmakers are diversifying their sourcing, building up inventory and looking harder at where critical ingredients and finished medicines are made. The World Health Organization now treats sustainable local manufacturing as a key part of resilient health systems and global health security. Its 2026 discussions have stressed stronger manufacturing ecosystems for medicines, vaccines and diagnostic products. Regulators are moving too. In 2026 the U.S. Food and Drug Administration launched its PreCheck pilot, which gets companies talking to regulators earlier while they develop new manufacturing facilities. The program aims at better regulatory predictability, along with more production capacity and stronger supply resilience. Quality Management Moves Beyond Compliance Good manufacturing practice is still the foundation of drug production, but regulators care more about whether manufacturers can hold quality steady over time. Under the FDA’s Quality Management Maturity program, manufacturers are urged to adopt practices beyond baseline current good manufacturing practice requirements. It aims at stronger quality culture, continuous improvement and less risk of supply disruption. Quality metrics are becoming practical management tools in this climate. Manufacturing teams can track measures like deviations, process performance, batch reliability and recurring quality issues to spot weaknesses before they turn into major failures. That shifts quality away from mostly inspection-driven work and toward a continuous manufacturing discipline. Advanced Manufacturing Changes Production More drug producers are adopting automation, continuous processing, advanced process controls and data-driven manufacturing systems. These tools can make processes more consistent and give manufacturers better visibility into production conditions. The FDA’s Advanced Manufacturing Technologies Designation Program exists to push wider adoption of technologies that can improve manufacturing reliability, product quality and drug supply. Digital systems support electronic batch records, laboratory integration, equipment monitoring and production analytics as well. Artificial intelligence could help with predictive maintenance, process monitoring and anomaly detection, though regulated uses need proper validation and governance. Technology pays off when it solves a specific manufacturing problem. Automation without solid process understanding can add complexity instead of improving performance. “Every technological and organizational improvement has to support the consistent manufacture of medicines that meet established standards for quality, safety and reliability.” Biologics Increase Manufacturing Complexity Drug portfolios are shifting toward products that demand far more sophisticated production capabilities. Biologics, biosimilars, cell and gene therapies and other complex products can require specialized facilities, sensitive processes and demanding analytical work. That means manufacturers need capabilities in process development, analytical testing, contamination control, coldchain management and specialized equipment. Flexibility in production is gaining value as product portfolios grow more diverse and batch sizes can swing widely. Contract development and manufacturing organizations have now become important partners for companies that want specialized capacity without building every capability in-house. Their value increasingly rests on technical depth, regulatory experience, technology transfer capability and reliable quality systems. Data Integrity Supports Manufacturing Reliability Drug production generates extensive data from manufacturing equipment, laboratory systems, environmental monitoring and quality processes. Records need to be accurate, attributable and traceable, since manufacturing decisions rest on that information. Data integrity is also closely tied to product quality. Poorly controlled electronic systems can create risks that reach beyond documentation. Batch release decisions, investigations and regulatory confidence can be affected. More manufacturers are combining production and quality data to find patterns across processes. Collecting more information isn’t the point in itself. Reliable data matters when it leads to earlier intervention and better process control. Sustainability Enters Facility Design Drug manufacturers also face mounting pressure to cut resource use and environmental impact. Facilities can consume large amounts of water, energy, solvents and specialized materials. Manufacturers are seeking gains in energy efficiency, solvent recovery, water optimization, waste reduction and more efficient production processes. Facility design is a good place to start, since environmental improvements are often easier to include during construction than after commissioning systems. Sustainability must still be weighed against validated production requirements. Changes to utilities, materials or processes can alter product quality, which calls for proper assessment and control. Regulatory Visibility Is Expanding Regulators are now looking harder at manufacturing networks, including facilities that contribute indirectly to the supply of finished medicines. In July 2026 the FDA proposed changes to clarify registration requirements for certain foreign establishments involved in drug and active pharmaceutical ingredient manufacturing, and to create a streamlined registration approach for some distributed manufacturing models. The proposal fits a wider move toward greater visibility across pharmaceutical supply chains. Manufacturers and sponsors need clearer insight into suppliers, manufacturing locations and dependencies that could affect product availability. The Outlook for Pharma Manufacturing Drug manufacturing is moving toward a model that pairs resilient supply networks, mature quality systems and advanced production technologies. The strongest manufacturers won’t necessarily be the ones with the biggest facilities. The winners will be companies that keep quality consistent while adapting production to changing product portfolios, regulatory expectations and supply conditions. Future competitiveness will depend on how well manufacturers connect science, engineering, quality and data. Drug production is getting more sophisticated, yet its core objective hasn’t changed. Every technological and organizational improvement has to support the consistent manufacture of medicines that meet established standards for quality, safety and reliability. ...Read more
In recent years, researchers combining computer science and biology have found it relatively easy to obtain funding to bring their innovations to the commercial market. The idea was simple: by leveraging large datasets, machine learning could overcome longstanding challenges in drug discovery, development, and testing. Nevertheless, many of these initial drug initiatives have encountered difficulties. It is crucial for both the field and patients to comprehend the reasons behind these setbacks and to address these developmental challenges. Patient Data is Fundamental Transferring cutting-edge knowledge from academic laboratories to address specific technical challenges using clearly defined datasets has been established as a successful strategy in technology and biotechnology. However, integrating Artificial Intelligence (AI) into medicine—frequently referred to as 'techbio'—tends to comprehensively emphasize biological aspects over technological ones. The data essential for success in this domain is typically more diverse, sourced from various locations, and, importantly, derived from actual patients within the intricate landscape of different healthcare environments. Staying Close to Academia: In the development of medicine, human intelligence must take precedence over artificial intelligence both initially and subsequently. This intelligence is predominantly found within universities and research hospitals. Therefore, a vital component in enhancing the efficacy of AI in the creation of superior medical solutions is the establishment of robust and enduring collaborations with these academic and research institutions. This process is not merely unidirectional; it constitutes a network of continuous engagement among academia, pharmaceutical companies, and biotechnology firms. Innovative collaboration methods, such as privacy-preserving federated learning, enable training machine learning models on extensive multimodal datasets without the need to transfer them. This approach can significantly advance fundamental research, diagnostics, and drug discovery, yielding numerous patient advantages while safeguarding privacy and optimizing the utilization of diverse data sources. Multi-Dimensional Problems Require Multimodal Data: At this point in the evolution of artificial intelligence within medicine, it is evident that AI provides us with a novel perspective on human biology. For instance, a single digital pathology slide encompasses a volume of data comparable to that of a feature-length film, and only through machine learning can we fully leverage this information. However, to comprehend diseases and influence their trajectories, it is crucial to acknowledge the intricate nature of biology across all levels—from molecules to cells, tissues, the disease microenvironment, and the organism in its entirety. To achieve this, advancing AI capabilities beyond unimodal tasks is imperative. We must integrate medical imaging with cutting-edge molecular profiling technologies that capture the activity and localization of biomolecules, known as spatial omics, thereby connecting the microscopic with the macroscopic. By combining AI with such comprehensive datasets, we can gain insights into diseases, from their predisposition to their progression and treatment. ...Read more
Drug discovery is a complex, multi-step process focused on identifying new therapeutic compounds and delivering them to market. Despite progress in technology and science, the path from discovery to an approved drug remains filled with challenges. These include high costs, extended timelines, and scientific uncertainties. This article examines the main hurdles in drug discovery and outlines strategies to overcome them. High Costs and Financial Risks One of the primary obstacles in drug discovery is the substantial financial burden linked to research and development (R&D). Typically, the process requires more than ten years and expenditures amounting to billions of dollars before introducing a new drug. The financial risk is substantial, as many potential drugs fail during clinical trials, leading to significant losses for pharmaceutical companies. Investment in Early-Stage Research: To mitigate financial risks, companies increasingly invest in early-stage research to identify promising compounds before committing to expensive clinical trials. Collaborations and Partnerships: Strategic partnerships with academic institutions, biotech firms, and other pharmaceutical companies can help share the financial burden and pool resources for drug development. Lengthy Timelines The drug discovery process is notoriously time-consuming. It involves multiple stages, including target identification; lead compound discovery, preclinical testing, and clinical trials. Each stage can take several years, and delays are common due to regulatory requirements and unforeseen scientific challenges. Streamlining Processes: Implementing efficient project management practices and leveraging technology can help streamline the drug discovery process. For example, using artificial intelligence (AI) and machine learning (ML) to analyze data can accelerate target identification and lead optimization. Regulatory Collaboration: Engaging with regulatory agencies early in development can help identify potential hurdles and expedite approval. Scientific Complexities Drug discovery is inherently complex due to the biological intricacies of diseases and the need for precise targeting of therapeutic compounds. Understanding disease mechanisms, identifying suitable targets, and designing effective drugs require advanced scientific knowledge and sophisticated technologies. Advanced Technologies: Cutting-edge technology such as CRISPR gene editing, high-throughput screening, and computer modeling can help us understand disease causes and improve medication design. Interdisciplinary Approaches: Combining expertise from various scientific disciplines, including biology, chemistry, and pharmacology, can result in more innovative solutions and a better understanding of complex biological systems. High Attrition Rates The attrition rate in drug discovery is notably elevated. Numerous compounds do not succeed in clinical trials owing to issues related to efficacy or safety. This high failure rate contributes to the cost and time required to develop new drugs. Predictive Models: The utilization of artificial intelligence and machine learning in the development of predictive models can facilitate the early identification of potential failures in the process, enabling researchers to concentrate their efforts on the most promising candidates. Biomarkers and Diagnostics: Incorporating biomarkers and diagnostic tools in clinical trials can improve patient selection and increase the likelihood of success by targeting specific populations more likely to respond to the treatment. ...Read more

Weekly Brief